Brief: Corcept Therapeutics Q2 EPS USD 0.29

Corcept Therapeutics Incorporated

31/07/2025 21:05

Overview

Corcept Q2 2025 revenue grows to $194.4 mln, missing analyst expectations, as per LSEG data

Net income for Q2 2025 slightly declines to $35.1 mln

The pharma company repurchased $115.4 mln of common stock in Q2 2025

Outlook

Corcept guides 2025 revenue at $850 mln to $900 mln

Company expects improved vendor performance to boost future quarters

Result Drivers

HYPERCORTISOLISM DEMAND - Increased recognition of hypercortisolism's prevalence led to more screenings and diagnoses, driving demand

VENDOR CAPACITY - Demand for hypercortisolism treatment outpaced specialty pharmacy vendor's capacity

EXPENSES RISE - Operating expenses increased significantly, impacting net income

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$194.43 mln
$199.40 mln (4 Analysts)
Q2 EPS
$0.29
Q2 Net Income
$35.15 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Corcept Therapeutics Inc is $138.50, about 49.5% above its July 30 closing price of $69.91

The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 49 three months ago

Press Release: ID:nBwbYnCwda

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)